GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (WBO:TKD) » Definitions » Change In Receivables

Takeda Pharmaceutical Co (WBO:TKD) Change In Receivables : €201 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Takeda Pharmaceutical Co Change In Receivables?

Takeda Pharmaceutical Co's change in receivables for the quarter that ended in Sep. 2024 was €-63 Mil. It means Takeda Pharmaceutical Co's Accounts Receivable increased by €63 Mil from Jun. 2024 to Sep. 2024 .

Takeda Pharmaceutical Co's change in receivables for the fiscal year that ended in Mar. 2024 was €93 Mil. It means Takeda Pharmaceutical Co's Accounts Receivable declined by €93 Mil from Mar. 2023 to Mar. 2024 .

Takeda Pharmaceutical Co's Accounts Receivable for the quarter that ended in Sep. 2024 was €4,415 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Takeda Pharmaceutical Co's Days Sales Outstanding for the three months ended in Sep. 2024 was 54.36.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Takeda Pharmaceutical Co's liquidation value for the three months ended in Sep. 2024 was €-35,400 Mil.


Takeda Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Takeda Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Change In Receivables Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -292.73 -71.99 974.75 524.96 92.75

Takeda Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.59 91.00 453.78 -280.97 -63.25

Takeda Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €201 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co  (WBO:TKD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Takeda Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4415.293/7412.246*91
=54.36

2. In Ben Graham's calculation of liquidation value, Takeda Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Takeda Pharmaceutical Co's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5711.626-48224.702+0.75 * 4415.293+0.5 * 7603.805
=-35,400

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co Headlines

No Headlines